发明名称 Compounds for the modulation of smn2 splicing
摘要 <p>The present invention relates to oligomer compounds (oligomers) which target nucleic acids encoding human SMN2 in a cell, leading to modulation of SMN2 mRNA splicing which favors full length SMN2 mRNA rather than the poorly functional truncated transcript, SMN2Δ7. Reduction of SMNA7 mRNA expression and/or increase in full length SMN2 mRNA expression are beneficial for the treatment of diseases or disorders associated with overexpression or undesirably high levels of aberrant forms of SMN2, particularly SMN2Δ7, such as spinal muscular atrophy (SMA).</p>
申请公布号 IL232380(D0) 申请公布日期 2014.06.30
申请号 IL20140232380 申请日期 2014.04.30
申请人 SANTARIS PHARMA A/S 发明人
分类号 C12N 主分类号 C12N
代理机构 代理人
主权项
地址